D A Nicoll - JoVE Visualize

Showing results (41-50 of 54) with videos related to

Pageof 6

Sort By:

Genomics|March 1, 1992

Mapping of the gene for the cardiac sarcolemmal Na(+)-Ca2+ exchanger to human chromosome 2p21-p23B H Shieh, Y Xia, R S Sparkes, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 17, 2001

In vitro metabolism of the COX-2 inhibitor DFU, including a novel glutathione adduct rearomatizationJ A Yergey, L A Trimble, J Silva, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 13, 2001

Application of rat hepatocyte culture to predict in vivo metabolic auto-induction: studies with DFP, a cyclooxygenase-2 inhibitorD A Nicoll-Griffith, J M Silva, N Chauret, et al.

Analytical Biochemistry|December 22, 1999

Description of a 96-well plate assay to measure cytochrome P4503A inhibition in human liver microsomes using a selective fluorescent probeN Chauret, N Tremblay, R L Lackman, et al.

The Journal of Biological Chemistry|July 1, 1994

Cloning of the NCX2 isoform of the plasma membrane Na(+)-Ca2+ exchangerZ Li, S Matsuoka, L V Hryshko, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 1, 1993

Characterization of verlukast metabolites arising from an epoxide intermediate produced with hepatic microsomes from beta-naphthoflavone-treated rodents (P-4501A1)D A Nicoll-Griffith, N Chauret, J A Yergey, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 20, 1998

Refinement of an in vitro cell model for cytochrome P450 inductionJ M Silva, P E Morin, S H Day, et al.

The Journal of Biological Chemistry|January 15, 1991

Identification of a peptide inhibitor of the cardiac sarcolemmal Na(+)-Ca2+ exchangerZ Li, D A Nicoll, A Collins, et al.

Bioorganic & Medicinal Chemistry Letters|May 1, 2001

In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663)N Chauret, J A Yergey, C Brideau, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 15, 2001

The use of 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) as a specific CYP2D6 probe in human liver microsomesN Chauret, B Dobbs, R L Lackman, et al.

Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:

Pageof 6

Genomics|March 1, 1992

Mapping of the gene for the cardiac sarcolemmal Na(+)-Ca2+ exchanger to human chromosome 2p21-p23B H Shieh, Y Xia, R S Sparkes, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 17, 2001

In vitro metabolism of the COX-2 inhibitor DFU, including a novel glutathione adduct rearomatizationJ A Yergey, L A Trimble, J Silva, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 13, 2001

Application of rat hepatocyte culture to predict in vivo metabolic auto-induction: studies with DFP, a cyclooxygenase-2 inhibitorD A Nicoll-Griffith, J M Silva, N Chauret, et al.

Analytical Biochemistry|December 22, 1999

Description of a 96-well plate assay to measure cytochrome P4503A inhibition in human liver microsomes using a selective fluorescent probeN Chauret, N Tremblay, R L Lackman, et al.

The Journal of Biological Chemistry|July 1, 1994

Cloning of the NCX2 isoform of the plasma membrane Na(+)-Ca2+ exchangerZ Li, S Matsuoka, L V Hryshko, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 1, 1993

Characterization of verlukast metabolites arising from an epoxide intermediate produced with hepatic microsomes from beta-naphthoflavone-treated rodents (P-4501A1)D A Nicoll-Griffith, N Chauret, J A Yergey, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 20, 1998

Refinement of an in vitro cell model for cytochrome P450 inductionJ M Silva, P E Morin, S H Day, et al.

The Journal of Biological Chemistry|January 15, 1991

Identification of a peptide inhibitor of the cardiac sarcolemmal Na(+)-Ca2+ exchangerZ Li, D A Nicoll, A Collins, et al.

Bioorganic & Medicinal Chemistry Letters|May 1, 2001

In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663)N Chauret, J A Yergey, C Brideau, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 15, 2001

The use of 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) as a specific CYP2D6 probe in human liver microsomesN Chauret, B Dobbs, R L Lackman, et al.

Pageof 6